[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.169.76. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
June 19, 2018

Germline Genetic Testing for Pancreatic Ductal Adenocarcinoma at Time of Diagnosis

Author Affiliations
  • 1Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 2Harvard Medical School, Boston, Massachusetts
  • 3Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2018;319(23):2383-2385. doi:10.1001/jama.2018.6227

Recent attention has focused on the hereditary basis of pancreatic ductal adenocarcinoma (PDAC), a fatal cancer with an overall 5-year survival of 8%.1 For inherited cancer syndromes such as Lynch and hereditary breast and ovarian cancer syndromes, research in the last 20 or more years has culminated in strategies for clinical management, with tailored screening, prophylactic surgery, and targeted therapies aimed at reducing the risk of cancer development or treating cancer in high-risk individuals and their family members. Strategies for identification and management of Lynch syndrome and hereditary breast and ovarian cancer syndrome have been formalized in several clinical guidelines that have been adopted by the medical community.

×